Marijuana Rescheduling Hits a New Deadline Today, With Court Fight Stretching Into 2027

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

The DOJ and challengers to the April 2026 Schedule III order jointly proposed a D.C. Circuit briefing schedule running to February 19, 2027, with no ruling date set, so the legal uncertainty is likely to last well into next year.

• Operators: The April order covers only marijuana under qualifying state medical licenses and FDA-approved drug products. Operators cannot assume Section 280E relief applies across all activities, so tax and reporting positions depend on which activities qualify.
• Investors: The order's survival is unresolved, and the separate DEA proceeding on broader rescheduling is stayed. Acquisition, financing and valuation decisions carry legal risk until the court rules and the DEA process concludes.
• Do now: Map each business line against the April order's covered categories and ask your tax adviser how Section 280E applies to each, under scenarios where the order stands or is struck down.

Short on time? You’re done. Want the numbers?Keep reading ↓

The legal battle over federal marijuana rescheduling is moving toward a new timetable that could keep the industry waiting well into 2027 for a judicial ruling.

Today, October 13, marks a separate procedural deadline in the Drug Enforcement Administration’s (DEA) rescheduling proceedings. Federal agencies must respond to a motion involving a Government Accountability Office (GAO) report that prompted a temporary stay in the administrative process. The deadline concerns the government’s response to that motion, not a final DEA decision on marijuana rescheduling.

Meanwhile, the U.S. Department of Justice and opponents of the Trump administration’s marijuana reclassification order submitted a joint proposed briefing schedule Friday, October 9, to the U.S. Court of Appeals for the District of Columbia Circuit.

Under the proposal, challengers would file their opening brief on November 24, the federal government would respond on January 13, 2027, and final written arguments would conclude on February 19.

The parties also requested oral arguments as soon as reasonably practicable after briefing concludes. The schedule remains subject to court approval, and no date has been established for a ruling.

What the Court Is Reviewing

The litigation concerns an April 2026 order issued by then-Acting Attorney General Todd Blanche that moved certain marijuana products into Schedule III of the Controlled Substances Act.

The order applies to marijuana covered by qualifying state medical marijuana licenses and marijuana drug products approved by the Food and Drug Administration. It does not constitute a blanket reclassification of all cannabis activity.

Three separate challenges to the order have been consolidated before the D.C. Circuit.

The challengers include Smart Approaches to Marijuana, the National Drug and Alcohol Screening Association, pharmaceutical companies, physicians and the attorneys general of Indiana and Nebraska.

The parties have agreed to coordinate their legal arguments into a consolidated opening brief and reply brief.

Meanwhile, the Justice Department is defending the administration’s action, while the petitioners challenge its legality and the authority under which it was issued.

In September, the appeals court declined to suspend the April order while litigation proceeds.

That decision allowed the existing Schedule III classification to remain in effect for the covered categories but did not determine whether the administration’s action was lawful.

A Separate DEA Proceeding Remains on Hold

The appeals court litigation is distinct from the Drug Enforcement Administration’s broader administrative proceeding to determine whether marijuana generally should move from Schedule I to Schedule III.

That proceeding encountered another delay on September 29, when DEA Chief Administrative Law Judge Derek C. Julius temporarily stayed the case.

The pause followed a request by opponents of rescheduling to introduce a Government Accountability Office report examining weaknesses in federal drug-scheduling procedures.

The GAO identified gaps in the policies and procedures used by federal agencies to evaluate controlled substances and develop scheduling recommendations.

The report did not conclude that marijuana should remain in Schedule I or that the federal government’s marijuana-specific evaluation was invalid.

Federal agencies were directed to respond to the request by October 13.

The judge must then determine whether to admit the report into the administrative record and allow additional briefing.

The administrative proceeding and the appeals court litigation therefore present separate questions: whether marijuana should be reclassified more broadly, and whether the administration’s existing, narrower reclassification order withstands judicial review.

Why the Timeline Matters for Cannabis Companies

For cannabis businesses, the distinction between the two proceedings has immediate financial significance.

Section 280E of the Internal Revenue Code restricts ordinary business deductions for companies trafficking in substances classified under Schedule I or II of the Controlled Substances Act.

Schedule III treatment can therefore materially change the federal tax position of qualifying cannabis operations.

However, the April order’s limited scope means companies cannot assume that every cannabis-related business activity automatically receives the same federal tax treatment.

The classification of particular operations, the application of Section 280E and the treatment of different business segments remain important considerations for financial reporting and tax planning.

The continuing litigation also complicates longer-term decisions involving acquisitions, financing and valuations.

For companies evaluating potential tax savings, the central question is not simply whether marijuana has moved to Schedule III. It is which activities qualify under the existing order, whether that order survives judicial review, and how the broader DEA proceeding ultimately concludes.

What Happens Next

The proposed appeals court timetable establishes several upcoming milestones.

Challengers would submit their consolidated opening brief on November 24, followed by the Justice Department’s response on January 13. Final briefs would be due February 19, 2027.

Oral arguments could follow, although the court has not established a hearing date.

Meanwhile, the DEA’s administrative process faces its own procedural decision following the October 13 deadline for federal agencies to respond to the request concerning the GAO report.

Neither proceeding has produced a final resolution of the broader question of federal marijuana scheduling.

For cannabis executives, lenders and investors, the next several months will require separating the benefits available under existing federal rules from the potential financial consequences of additional regulatory changes.

These legal and financial questions will also be part of the conversation at IgniteIt’s Capital & Policy Summit in Washington, D.C., on November 18, where industry leaders will examine the federal policy developments shaping cannabis investment, taxation, and business strategy.